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ABSTRACT
Objective: Data on early risk of infection in patients
receiving their first treatment for type 2 diabetes are
limited. We examined rates of community-based
antibiotic use and hospital-treated infection in initiators
of metformin and other glucose-lowering drugs
(GLDs).
Design: Population-based cohort study using medical
databases.
Setting: General practice and hospitals in Denmark.
Participants: 131 949 patients with type 2 diabetes
who initiated pharmacotherapy with a GLD between
2005 and 2012.
Exposure: Initial GLD used for pharmacotherapy.
Main outcome measures: We computed rates and
adjusted HRs of community-based antibiotic use and
hospital-treated infection associated with choice of
initial GLD with reference to metformin initiation, using
an intention-to-treat approach.
Results: The rate of community-based antibiotic use
was 362 per 1000 patient-years at risk (PYAR) and that
for hospital-treated infection was 51 per 1000 PYAR.
Compared with metformin, the risk of hospital-treated
infection was slightly higher in sulfonylurea initiators
(HR 1.12, 95% CI 1.08 to 1.16) and substantially
higher in insulin initiators (HR 1.63, 95% CI 1.54 to
1.72) initiators after adjustment for comorbid
conditions, comedications and other confounding
factors. In contrast, virtually no difference was
observed for overall community-based antibiotic use
(HR 1.02, 95% CI 1.01 to 1.04, for sulfonylurea
initiators; and 1.04, 95% CI 1.01 to 1.07, for insulin
initiators).
Conclusions: Rates of community-based antibiotic
treatment and hospitalisation for infection were high in
patients receiving their first treatment for type 2
diabetes and differed with the choice of initial GLD
used for pharmacotherapy.
INTRODUCTION
Glucose-lowering drugs (GLDs) are pre-
scribed increasingly in patients with type 2
diabetes,1 with the aim of reducing macrovas-
cular and microvascular complications.
Three out of four patients diagnosed with
diabetes initiate pharmacotherapy within the
following year.2 Although infections are a
major clinical problem and an important
cause of death in patients with type 2 dia-
betes,3 4 population-based data are scarce on
early infection risk in patients initiating GLD
pharmacotherapy.
It has been observed recently that metfor-
min use is associated with reduced risk of
infections after surgery5 and reduced risk of
septicaemia,6 with improved prognosis follow-
ing septicaemia and other critical illness,7
and with a beneﬁcial effect on prevention
and treatment of respiratory tract infections
due to Staphylococcus aureus.8 Limited epi-
demiological data are available comparing
the association of different GLDs with risk of
infections.6 9 In a Swedish study based on
51 675 patients with type 2 diabetes treated
Strengths and limitations of this study
▪ Large nationwide population-based study based
on prospectively collected data from hospitals
and general practices.
▪ Comprehensive list of infections and antibiotics
studied in people receiving their first treatment
for type 2 diabetes.
▪ Main limitation was possible residual confound-
ing by differences in diabetes severity.
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with GLDs between 2004 and 2007, the HR of hospital-
isation for infection with co-occurrence of acidosis was
greater for insulin monotherapy users (HR 1.37, 95% CI
1.26 to 1.50) and other oral GLDs users (80% sulfony-
lurea) (HR 1.16, 95% CI 1.04 to 1.28) compared with
metformin users.9 Another study of 43 015 cases with
septicaemia and control participants nested in a cohort
of newly diagnosed type 2 diabetes patients from Taiwan
found that metformin use was associated with reduced
risk of developing septicaemia (OR 0.80, 95% CI 0.77 to
0.83) compared with metformin non-users.6 For other
infections including those treated by general practi-
tioners, comprehensive data on the risk among users of
different GLDs are lacking.
Therefore, we undertook a large cohort study using
nationwide Danish population data to investigate rates of
community-based antibiotic use and hospital-treated
infection associated with initiation of different GLDs in
type 2 diabetes patients.
METHODS
Data sources
We used the Danish National Patient Registry (DNPR),10
the Danish National Health Service Prescription
Database (DNHSPD)11 and the Danish Civil Registration
System (CRS)12 to conduct this study. The Danish
National Health Service provides Danish residents with
universal access to general practice and hospitals and
reimburses most of the cost of prescription drugs,
including GLDs.11 We used the unique central personal
registry (CPR) number to link individual-level data
among registries. The CRS began to assign a CPR
number to all residents at birth or upon immigration in
1968.12 Since then, the CRS has maintained daily
updated records of date of death or emigration, previous
and current place of residence, marital status and CPR
number for all Danish residents. The DNPR contains
nationwide information on all hospitalisations since
1977 and on all outpatient and emergency room visits
since 1995.10 It records patients’ CPR number, a primary
discharge diagnosis and up to 19 secondary discharge
diagnoses coded according to the International
Classiﬁcation of Diseases, Eighth Revision (ICD-8) until the
end of 1993, and Tenth Revision (ICD-10) thereafter. The
DNHSPD collects data from all community pharmacies
and hospital-based outpatient pharmacies. It has
archived patient-related, drug-related and prescriber-
related information on all prescription medications dis-
pensed in Denmark since 2004.11 The drugs are coded
according to the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system.
Study design and population
We conducted this population-based cohort study in a
Danish nationwide cohort of patients with an incident
type 2 diabetes diagnosis recorded between 1 January
2005 and 31 December 2012. Incident type 2 diabetes
was deﬁned as either the ﬁrst record in the DNPR of a
diabetes-associated inpatient admission (data available
from 1977) or outpatient clinic contact (data available
from 1995) or the ﬁrst record of a GLD prescription in
the DNHSPD (data available from January 2004), which-
ever came ﬁrst.13 To decrease the chance of including
patients with type 1 diabetes, we restricted our cohort to
patients who were 30 years or older when ﬁrst diagnosed
with diabetes (n=147 396).14 We also excluded patients
with a diabetes diagnosis but no recorded GLD prescrip-
tion during the 2005–2012 study period (n=14 120).
Women with a recorded diagnosis of polycystic ovarian
disease who were using metformin monotherapy, identi-
ﬁed from the DNPR and the DNHSPD, were excluded
as well (n=1327). This left a ﬁnal study cohort of
131 949 patients with incident pharmacotherapy for type
2 diabetes.
We deﬁned exposure as the ﬁrst record of a redeemed
GLD prescription in the DNHSPD (the index date)
between 2005 and 2012. We disregarded any change or
addition of other GLD afterwards. We established seven
mutually exclusive categories of exposure according to
the type of ﬁrst-prescribed GLD: metformin (bigua-
nides); sulfonylurea; insulin; any ﬁxed drug combina-
tions; dipeptidyl peptidase-4 (DPP-4) inhibitors;
glucagon-like peptidase-1 (GLP-1) analogue; megliti-
nides; other (including thiazolidinediones; and α gluco-
sidase inhibitors) (see online supplementary appendix 1
for ATC codes). We followed the study cohort from the
index date until death, emigration or end of the study
period (31 December 2012), whichever came ﬁrst.
Assessment of outcomes
Our outcomes were hospital-treated infections and
community-based antibiotic use. Hospital-treated infec-
tion was deﬁned as any ﬁrst inpatient admission or out-
patient hospital clinic contact associated with a primary
or secondary discharge diagnosis of infection after the
index date. We further divided hospital-treated infec-
tions into subcategories (see online supplementary
appendix 1 for categories and associated ICD codes).
Community-based antibiotic use was deﬁned as any
ﬁrst record of an antibiotic prescription in the DNHSPD
that was redeemed during the study period after the
index date. We investigated 10 groups of antibiotics pre-
scribed to treat speciﬁc infections according to national
Danish guidelines for general practitioners (see online
supplementary appendix 1 for ATC codes).15 16
Assessment of covariates
We searched the DNPR for information on 19 major
comorbidities included in the Charlson comorbidity
index (CCI),17 based on each cohort member’s entire
hospital contact history during the 10 years prior to his/
her index date. We deﬁned three comorbidity levels: low
(CCI score of 0), medium (CCI scores of 1 or 2) and
high (CCI score ≥3).18 We also collected information on
other covariates associated with risk of infection:
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microvascular and macrovascular diabetes complications
not included in the CCI (see online supplementary
appendix 1); diabetes duration (if a hospital diagnosis
was present before the GLD initiation/index date); pres-
ence of alcoholism-related disorders (yes/no); a hospital
diagnosis of obesity (yes/no); use of immunosuppressive
drugs (yes/no), oral corticosteroids (yes/no) or statins
(yes/no); marital status as a marker of social support
(married/never married/divorced/widowed); and calen-
dar period of inclusion (2005–2008/2009–2012).
Statistical analysis
We described cohort characteristics at the time the ﬁrst
GLD was redeemed according to GLD categories
(table 1). We used an intention-to-treat approach19 and
computed incidence rates (IRs) separately for
community-based antibiotic use and for hospital-treated
infections, by dividing the number of incident outcome
events by total exposed patient-time during follow-up
(expressed per 1000 patient-years at risk (PYAR)). We
then used the Cox regression to compute HRs of
community-based antibiotic use and hospital-treated
infections (with 95% CIs) associated with the exposure
categories described above, using metformin initiation
as reference. We computed estimates adjusted for age
and sex (Model 1) and estimates fully adjusted for all
available confounders (Model 2) (see above). We
repeated the analyses for speciﬁc infections and anti-
biotic groups, except for those associated with four or
fewer events during complete follow-up.
Bias and sensitivity analyses
Increased body mass index (BMI) and tobacco smoking
may be associated with type 2 diabetes, choice of dia-
betes therapy and infection risk. As we had data only on
hospital-diagnosed obesity and tobacco-related diseases,
and no detailed data on smoking or BMI, we computed
externally adjusted estimates of unmeasured obesity
(BMI ≥30 kg/m2) and smoking, respectively, and com-
pared them with our crude estimates, to assess the pro-
portion of effect possibly explained by obesity or
smoking alone, using the array approach as presented
by Schneeweiss:20
caHR ¼ aHRðPc1ðHRcd 1)þ 1)/(Pc0(HRcd 1)þ 1)
ð1Þ
where caHR is the obesity-adjusted HR, aHR the crude
rate ratio observed in our study, Pc0 the proportion of
patients with obesity in the reference (metformin)
group (estimated at 0.49 in the study period based on
the study by Ulrichsen et al),21 Pc1 the proportion of
patients with obesity in the exposed group (for insulin,
0.19; for sulfonylurea, 0.26)21 and HRcd is the expected
rate ratio of infection related to obesity (1.5 for hospital-
treated infections and 1.23 for community-based anti-
biotic use).16 Similarly, we computed externally adjusted
estimates for tobacco smoking (Pc0=0.22, Pc1 for
insulin=0.26, Pc1 for sulfonylurea=0.30, HRcd for
hospital-treated infection=4.1 and HRcd for antibiotic
use=1.17).21–23 Additionally, using a rule-out approach,20
we estimated how strongly a single unmeasured binary
confounder (eg, BMI, smoking) would need to be asso-
ciated with the choice of GLD and infection to fully
explain our adjusted results. We repeated this sensitivity
analysis for the observed lower limit of the 95% CI of
the adjusted HR. We describe the details of the methods
and the choice of parameter in online supplementary
appendix 2. Finally, for a subcohort of our study popula-
tion (n=33 795), we had additional information on latest
glycated haemoglobin (HbA1c) level before GLD initi-
ation (baseline HbA1c). We repeated the analyses for
this subcohort including baseline HbA1c categories (ref-
erence category: 5.5%–6.5%) as an additional confoun-
der in the fully adjusted model.
We used SAS software (V.9.1.3; SAS Institute, Cary,
North Carolina, USA) for data management. Analyses
were carried out using STATA V.12 (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station,
Texas, USA: StataCorp LP). The study was approved by
the Danish Data Protection Agency (record numbers
2012-41-0793 and 2013-41-1924).
RESULTS
Cohort characteristics
Of the 131 949 type 2 diabetes patients receiving their
ﬁrst antidiabetic medication, 106 424 (81%) started with
metformin, 16 703 (13%) started with sulfonylurea and
7293 (6%) started with insulin. Only 1529 (<1%) indivi-
duals used one of the other GLDs as their initial
drug (table 1). In our study cohort, 56% (74 391) were
men and the median age at inclusion was 62 years (IQR
52–70 years). Compared with type 2 diabetes patients
who used metformin as their ﬁrst drug, sulfonylurea
initiators were older (median age 67 years vs 62 years),
more likely to be enrolled before 2008 (80% vs 35%),
more likely to change therapy within 1 or 2 years (22%
and 33% vs 16% and 21%, respectively) and more likely
to have comorbidities (39% vs 29%), diabetes-related
macrovascular complications (26% vs 21%) or
alcoholism-related conditions (4% vs 2%) (table 1).
Patients who initiated their therapy with sulfonylurea
also had less hospital-diagnosed obesity (4% vs 9%), and
were less likely to be using statins at the time of GLD ini-
tiation (37% vs 48%).
Insulin initiators were younger (median age 56 vs
62 years); more likely to have been included in the study
before 2008 (51% vs 35%); more likely to have
comorbidities (45% vs 29%), microvascular complica-
tions (10% vs 6%) and alcoholism-related conditions
(10% vs 2%); less likely to be using statins (21% vs
48%); and more likely to have changed their therapy
within 1 or 2 years (24% and 27% vs 16% and 21%,
respectively) than metformin initiators (table 1).
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Table 1 Baseline characteristics of 131 949 patients with type 2 diabetes, according to initial pharmacotherapy with glucose-lowering drugs (2005–2012)
Characteristics Metformin Sulfonylurea Insulin
Fixed drug
combinations
DPP-4
inhibitors
GLP-1
analogues Meglitinides Other Total
n (%)* 106 424 (81) 16 703 (13) 7293 (6) 553 (<1) 358 (<1) 295 (<1) 231 (<1) 92 (<1) 131 949 (100)
Sex
Men 59 213 (56) 9879 (59) 4421 (61) 355 (64) 212 (59) 126 (43) 128 (55) 57 (62) 74 391 (56)
Women 47 211 (44) 6824 (41) 3872 (39) 198 (36) 146 (41) 169 (57) 103 (45) 35 (38) 57 558 (44)
Age in years
Median age (IQR) 62 (52, 70) 67 (57, 76) 56 (43, 68) 62 (52, 70) 67 (56, 76) 52 (44, 61) 62 (53, 72) 58 (46, 69) 62 (52, 70)
Age-groups (years)
30 to <50 22 611 (21) 2026 (12) 2728 (37) 124 (22) 41 (11) 128 (43) 49 (21) 28 (830) 27 735 (21)
50 to <70 58 184 (55) 7835 (47) 3050 (42) 291 (53) 182 (51) 143 (48) 116 (50) 43 (47) 69 844 (53)
>70 25 629 (24) 6842 (41) 1515 (21) 138 (25) 135 (38) 24 (8) 66 (29) 21 (23) 34 370 (26)
Year of study inclusion
2005–2008 37 692 (35) 13 433 (80) 3702 (51) 181 (33) 123 (34) 5 (2) 174 (75) 53 (58) 55 363 (42)
2009–2012 68 732 (65) 3270 (20) 3591 (49) 372 (67) 235 (66) 290 (98) 57 (25) 39 (42) 76 586 (58)
Marital status
Married 64 123 (61) 9630 (59) 4062 (58) 322 (59) 214 (60) 196 (66) 157 (69) 59 (64) 78 763 (60)
Never married 13 404 (13) 1271 (8) 1211 (17) 85 (16) 34 (10) 55 (19) 13 (6) 10 (11) 16 083 (12)
Divorced 15 457 (15) 2150 (13) 1080 (15) 85 (16) 46 (13) 32 (11) 22 (10) 17 (18) 18 889 (14)
Widowed 12 561 (12) 3269 (20) 701 (10) 55 (10) 60 (17) 12 (4) 36 (16) 6 (7) 16 700 (13)
CCI score
Low (score of 0) 75 550 (71) 10 224 (61) 3953 (54) 385 (70) 202 (56) 207 (70) 154 (67) 54 (59) 90 729 (69)
Medium (scores of 1–2) 25 957 (24) 5035 (30) 2076 (28) 134 (24) 110 (31) 72 (24) 59 (26) 28 (30) 33 471 (25)
High (score ≥3) 4917 (5) 1444 (9) 1264 (17) 34 (6) 46 (13) 16 (5) 18 (8) 10 (11) 7749 (6)
Diabetes complications
No complications 77 981 (73) 10 968 (66) 5024 (69) 417 (75) 204 (57) 237 (80) 168 (73) 71 (77) 95 070 (72)
Microvascular 6422 (6) 1423 (9) 729 (10) 33 (6) 31 (9) 16 (5) 22 (10) 6 (7) 8682 (7)
Macrovascular 22 021 (21) 4312 (26) 1540 (21) 103 (19) 123 (34) 42 (14) 41 (18) 15 (16) 28 197 (21)
Alcoholism-related conditions 2651 (2) 595 (4) 742 (10) 12 (2) 17 (5) 4 (2) 10 (4) 3 (3) 4034 (3)
Hospital-diagnosed obesity 9566 (9) 602 (4) 528 (7) 46 (8) 28 (8) 79 (27) 7 (3) 17 (18) 10 873 (8)
Hospital outpatient follow-up in first year
after study inclusion
16 463 (15) 3502 (21) 1695 (23) 86 (16) 62 (17) 18 (6) 33 (14) 11 (12) 21 870 (17)
Therapy change during follow-up 30 845 (29) 9977 (60) 2353 (32) 259 (47) 173 (48) 48 (16) 135 (58) 41 (45) 43 831 (33)
Therapy change within 1-year 16 530 (16) 3618 (22) 1752 (24) 140 (25) 122 (34) 31 (11) 62 (27) 23 (25) 22 278 (17)
Therapy change within 2 years 21 877 (21) 5581 (33) 1970 (27) 184 (33) 147 (41) 45 (15) 86 (37) 33 (36) 29 923 (23)
Number of patients with HbA1c
measurement
27 200 (56) 4576 (59) 1649 (61) 164 (64) 115 (59) 35 (43) 34 (55) 22 (62) 33 795 (56)
Median % HbA1c (IQR) 7.1 (6.5, 8.3) 7.6 (6.9, 9.2) 10.1 (7.5, 12.1) 8.3 (7.0, 10.6) 7.0 (6.5, 7.7) 6.4 (6.0, 7.3) 7.1 (6.1, 7.9) 7.0 (5.9, 7.8) 7.2 (6.6, 8.7)
Other medication use
Statins 50 817 (48) 6230 (37) 1522 (21) 230 (42) 167 (47) 80 (27) 63 (27) 24 (26) 59 163 (45)
Immunosuppressants 669 (1) 134 (1) 85 (1) 2 (<1) 3 (1) 4 (1) 2 (1) 5 (5) 904 (1)
Corticosteroids 3825 (4) 1163 (7) 1044 (14) 20 (4) 21 (6) 11 (4) 15 (6) 6 (7) 6105 (5)
*Parentheses contain percentages unless otherwise specified.
CCI, Charlson comorbidity index; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin.
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Rates of community-based antibiotic use and
hospital-treated infections
During 218 032 PYAR, we identiﬁed 78 847 events (60%
of all patients), yielding an IR of 361.8 per 1000 PYAR
(95% CI 359.2 to 364.3). The IRs of community-based
antibiotic use were higher in patients who initiated their
treatment with insulin compared with those who
initiated with sulfonylurea or metformin (see online sup-
plementary table S1). We identiﬁed 20 308 (15%)
initial-onset hospital-treated infection events during
395 171 PYAR, yielding an overall IR of 51.4 per 1000
PYAR (95% CI 50.7 to 52.1). IRs of hospital-treated
infections were highest in patients who initiated their
treatment with insulin, followed by patients who initiated
with sulfonylurea and metformin (see online supple-
mentary table S1). Cumulative rates of community-based
antibiotic prescriptions and hospital-treated infections
within the ﬁrst 4 years in patients who initiated their
treatment with metformin, sulfonylurea or insulin are
illustrated in ﬁgure 1. The figure shows that infection
rates increased most sharply shortly after GLD treatment
initiation. The unadjusted curves for the three treatment
modalities diverged early during follow-up, with insulin
initiators experiencing more infections than sulfonylurea
initiators throughout follow-up, and sulfonylurea initia-
tors experiencing more infections than metformin initia-
tors (log-rank test for equality of survival function
between the three exposure groups, p<0.00001 for both
outcomes) (ﬁgure 1).
Community-based antibiotic use
Compared with patients who initiated their treatment
with metformin, the crude risk of subsequent
community-based antibiotic prescriptions was increased
in patients who initiated treatment with sulfonylurea
(crude HR 1.06, 95% CI 1.04 to 1.08). The HR
remained stable even after adjusting for age and
sex (HR 1.05, 95% CI 1.03 to 1.07), but reduced to
1.02 (95% CI 1.01 to 1.04) in the fully adjusted
model (table 2). For speciﬁc antibiotic groups, patients
who initiated antidiabetic treatment with sulfonylurea
were at increased risk of treatment for infection with azi-
thromycin (adjusted HR 1.10, 95% CI 1.03 to 1.17), qui-
nolones (adjusted HR 1.43, 95% CI 1.12 to 1.84),
antibiotics used to treat urinary tract infection (UTI)
(adjusted HR 1.07, 95% CI 1.03 to 1.11) and other broad-
spectrum antibiotics (adjusted HR 1.07, 95% CI 1.03 to
1.11) (ﬁgure 2 and see online supplementary table S2).
Similarly, the risk of community-based antibiotic use in
patients who initiated their treatment with insulin
decreased from 1.13 (95% CI 1.09 to 1.16) to 1.04 (95%
CI 1.01 to 1.07) in the fully adjusted model (table 2).
For speciﬁc antibiotic groups, insulin initiators had
increased risks of subsequent treatment of infections
with quinolones (adjusted HR 4.36, 95% CI 3.36 to
5.65), cephalosporins (adjusted HR 4.65, 95% CI 2.16 to
10.01), dicloxacillin/ﬂucloxacillin (adjusted HR 1.16,
95% CI 1.09 to 1.24) and with antibiotics used to treat
UTI (adjusted HR 1.17, 95% CI 1.11 to 1.24) (ﬁgure 2
and see online supplementary table S2).
In sensitivity analyses for sulfonylurea versus metfor-
min, external adjustment for unmeasured obesity (lower
with sulfonylurea) changed the crude HR from 1.06 to
1.11 and for smoking (higher with sulfonylurea)
changed the crude HR from 1.06 to 1.05, respectively.
For insulin versus metformin, external adjustment for
unmeasured obesity changed the crude HR from 1.13 to
1.20 and for smoking changed the crude HR from 1.13
to 1.12, respectively. The rule-out sensitivity analysis sug-
gested that had we been able to account for obesity, we
would likely have observed an association of antibiotic
use with sulfonylurea or insulin compared with metfor-
min that was stronger than we observed, as obesity is
more prevalent among metformin users than the other
treatment (see online supplementary appendix 2 for
details). In contrast, had we been able to account for
more smoking in sulfonylurea or insulin compared with
metformin users, this might have nulliﬁed our weakly
Figure 1 Kaplan-Meier curves
showing cumulative rates of
community-based antibiotic
prescriptions and hospital-treated
infections as percentages within
the first 4 years following
treatment initiation with
metformin, sulfonylurea or insulin.
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increased antibiotic HRs. For example, if smoking were
1.3-fold more prevalent among sulfonylurea than metfor-
min users, the relatively likelihood of being prescribed
antibiotics would have to be about 50% greater in those
who smoke for the HR to be ≤1, which is plausible from
ﬁndings in the literature21 (see online supplementary
ﬁgure S1.4 in appendix 2).
We performed further analyses on the subcohort of
patients with baseline HbA1c information. Compared
with those who initiated their treatment with metformin,
patients ﬁrst treated with sulfonylurea and insulin had
adjusted HRs of community-based antibiotic use of 1.05
(95% CI 1.01 to 1.10) and 1.03 (95% CI 0.96 to 1.11),
respectively (vs 1.02, 95% CI 1.00 to 1.04, and 1.04, 95%
CI 1.01 to 1.07 in the full cohort). After additional
adjustment for baseline HbA1c, the HRs did not change
for sulfonylurea initiators (adjusted HR 1.05, 95% CI
1.01 to 1.10), but increased slightly for insulin initiators
(adjusted HR 1.08, 95% CI 1.00 to 1.17) (see online sup-
plementary table S3).
The HRs were not increased for the rest of the rarer
GLD categories (table 2). For GLDs other than sulfony-
lurea and insulin, the HRs and number of infections (if
≤4) treated with speciﬁc antibiotic groups are provided
in online supplementary table S2.
Hospital-treated infections
Compared with patients who initiated treatment with
metformin, the risk of hospital-treated infections was
higher in patients who initiated treatment with sulfony-
lurea (HR 1.41, 95% CI 1.36 to 1.46). The HR was
reduced to 1.20 (95% CI 1.16 to 1.24) in Model 1 and
further reduced to 1.12 (95% CI 1.08 to 1.16) in fully
adjusted Model 2 (table 2). Patients who initiated their
treatment with sulfonylurea had increased risk of hospi-
talisation for viral infections (adjusted HR 1.70, 95% CI
1.40 to 2.07), fungal infections (adjusted HR 1.45, 95%
CI 1.15 to 1.83), intra-abdominal infections (adjusted
HR 1.27, 95% CI 1.14 to 1.41), bacterial infections
(adjusted HR 1.27, 95% CI 1.07 to 1.50), UTI (adjusted
HR 1.08, 95% CI 1.01 to 1.17), pneumonia (adjusted
HR 1.19, 95% CI 1.12 to 1.26) and septicaemia
(adjusted HR 1.12, 95% CI 1.02 to 1.24) compared with
those who initiated treatment with metformin (ﬁgure 3
and see online supplementary table S4).
The risk of hospital-treated infections was twice as high
in patients initiating treatment with insulin compared
with metformin initiators (HR 1.96, 95% CI 1.87 to 2.07),
and the association strengthened after adjusting for age
and sex (HR 2.28, 95% CI 2.17 to 2.39). After inclusion
of other confounders, the HR decreased to 1.63 (95% CI
1.54 to 1.72) in the full model (table 2). Type 2 diabetes
patients who initiated treatment with insulin had a
greater risk of hospitalisation for nearly all examined
infections in particular fungal infections (adjusted HR
2.45, 95% CI 1.82 to 3.29), tuberculosis (adjusted HR
2.39, 95% CI 1.11 to 5.14), infections of the heart and
blood vessels (adjusted HR 2.13, 95% CI 1.21 to 3.75)
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and septicaemia (adjusted HR 2.10, 95% CI 1.84 to 2.40),
compared with patients who initiated treatment with met-
formin (ﬁgure 3 and see online supplementary table S4).
In sensitivity analyses for sulfonylurea versus metfor-
min, external adjustment for unmeasured obesity
changed the crude HR from 1.41 to 1.55, while external
adjustment for smoking decreased the HR to 1.23,
respectively. For insulin versus metformin, external
adjustment for unmeasured obesity (lower with insulin)
increased the crude HR from 1.96 to 2.23 and decreased
to 1.83 after external adjustment for smoking (more
with insulin). The rule-out approach of sensitivity ana-
lyses illustrated that for hospital-treated infections,
neither obesity nor smoking could completely explain
the observed association in our study (see online supple-
mentary appendix 2 for details). For example, if obesity
were 1.6-fold more frequent among sulfonylurea users
than metformin users, the relative likelihood of hospital-
treated infections would have to be increased by a factor
of three or more to explain our ﬁndings fully, if no
increased risk actually existed, which is unlikely based
on available literature21 (see online supplementary
ﬁgure S2.2 in appendix 2).
In the subcohort with available baseline HbA1c infor-
mation, pre-treatment HbA1c decreased from insulin to
sulfonylurea to metformin initiators; however, baseline
HbA1c per se was not a strong predictor of infection risk
(data not shown). When using treatment initiation with
Figure 2 Adjusted HRs of
specific antibiotic therapies
associated with pharmacotherapy
initiation with sulfonylureas versus
metformin (shown as blue
diamonds) and insulin versus
metformin (shown as red
squares), in patients with type 2
diabetes. M, S and I denote total
number or hospital-treated
infections in metformin,
sulfonylurea and insulin initiators,
respectively.
Figure 3 Adjusted HRs of specific hospital-treated infections associated with pharmacotherapy initiation with sulfonylureas
versus metformin (shown as blue diamonds) and insulin versus metformin (shown as red squares), in patients with type 2
diabetes. M, S and I denote total number or hospital-treated infections in metformin, sulfonylurea and insulin initiators,
respectively.
Mor A, et al. BMJ Open 2016;6:e011523. doi:10.1136/bmjopen-2016-011523 7
Open Access
group.bmj.com on October 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
metformin as the comparator, adjusted HRs of hospital-
treated infection associated with sulfonylurea and
insulin initiation in the subcohort were 1.17 (95% CI
1.08 to 1.26) and 1.88 (95% CI 1.69 to 2.1), respectively
(vs 1.12 and 1.63 in the full cohort). Additional adjust-
ment for baseline HbA1c did not change the adjusted
HR for sulfonylurea initiators (adjusted HR 1.17, 95%
CI 1.08 to 1.26), and increased it slightly for insulin
initiators (adjusted HR 1.96, 95% CI 1.73 to 2.22) (see
online supplementary table S3).
Few episodes of infection occurred in patients taking
medication in the remaining small GLD categories, and
we did not detect a clear difference compared with met-
formin (table 2). For GLDs other than sulfonylurea and
insulin, the HRs and number of hospital contacts (if ≤4)
for speciﬁc infections are provided in online supplemen-
tary table S4.
DISCUSSION
In this study of patients with type 2 diabetes treated
pharmacologically for the ﬁrst time, we found high rates
of community-based antibiotic treatment and hospitalisa-
tions for infection during follow-up. We also found that
patients who initiated pharmacotherapy with insulin,
and to less extent those who initiated sulfonylurea, were
at increased risk of hospital-treated infection compared
with those who initiated pharmacotherapy with metfor-
min. In contrast, there was little difference in rates of
community-based antibiotic use between initiators of dif-
ferent GLDs.
Our results corroborate ﬁndings from the Swedish
study that reported an increased risk of hospitalisation
for infection among patients who initiated their pharma-
cotherapy with insulin alone (HR 1.37, 95% CI 1.26 to
1.50) or with other oral GLDs (other than metformin)
(HR 1.16, 95% CI 1.04 to 1.28), compared with metfor-
min.9 Furthermore, our results are in line with the
observed reduced odds of septicaemia in metformin
users versus metformin never users (OR 0.80, 95% CI
0.77 to 0.83) and increased odds in sulfonylurea users
versus sulfonylurea never users (OR 1.06, 95% CI 1.03 to
1.10) in the nationwide cohort of GLD-treated type 2
diabetes patients from Taiwan.6 Few comparative studies
have examined newer second-line GLDs.24 25 Although
statistically imprecise, our results are in line with those
from a double-blind randomised study of 807 type 2 dia-
betes patients, in which 3% of patients treated with met-
formin and 6% of patients treated with DPP-4 inhibitors
experienced an upper respiratory tract infection (URTI)
event during a follow-up period of 52 weeks (p >0.05).25
Our results support a recent systematic review and
meta-analysis of 19 randomised controlled trials that
found no difference in risk of UTI (RR 0.86, 95% CI
0.51 to 1.45) between patients receiving DPP-4 inhibitors
and those receiving metformin.24
Hyperglycaemia may be a risk factor for infections in
patients with type 2 diabetes.26–30 Therefore, GLDs in
theory might inﬂuence risk of infections via their
different glucose-lowering mechanisms and effectiveness.
Hyperglycaemia seems to weaken innate immunity via its
negative inﬂuence on polymorphonuclear neutrophil
function and intracellular bactericidal and opsonic activ-
ity.31 Insulin is more effective in reducing blood glucose
than sulfonylureas and metformin;32 and insulin has
been suggested to enhance innate and cell-mediated
immunity33 and promote macrophage function.31 34
This contrasts with our observation that insulin initiators
had the highest risk of infections. Other non-glycaemic
effects of GLDs on the immune system might be at
play.31 33 35–37 It has been suggested that the 5′
AMP-activated protein kinase activation property of met-
formin facilitates neutrophil-dependent bacterial uptake
and killing associated with inhibition of neutrophil acti-
vation and chemotaxis.36 37 This mechanism might con-
tribute to the lower risk of infections in patients taking
metformin versus insulin or sulfonylureas.9 Apart from
the inhibitory effect of sulfonylureas on inﬂammasome
assembly, evidence is sparse on their association with
immune regulation.35 Thus, while the mechanisms
underlying the association of different GLDs with infec-
tion remain unclear,38 our results support metformin as
the preferred ﬁrst-line drug in treatment algorithms
from the point of view of infections.
The main strengths of our study are its population-
based design, the large nationwide cohort of patients
with type 2 diabetes and virtually no loss to follow-up
(<1%). The use of high-quality medical databases to
identify infections treated in the community and in the
hospital setting ensured inclusion of nearly all diagnosed
infections.
Nonetheless, observational studies of the comparative
effects of diabetes drugs have several major methodo-
logical challenges.39 Therefore, our results for different
therapies should be interpreted with caution, bearing in
mind the limitations of this routine registry-based study.
A main limitation was lack of accurate data on clinical
severity of diabetes, which might have led to residual
confounding by indication.40 Nevertheless, increased
clinical severity of type 2 diabetes (including complica-
tions such as early signs of renal disease, or indicators of
less insulin production), other contraindications to met-
formin and/or anticipated worse glucose derangement
may have led physicians to initiate treatment with sulfo-
nylurea and particularly insulin instead of metformin.
This may be supported by our observation that sulfony-
lurea and insulin initiators had more subsequent
therapy shifts than metformin initiators, possibly related
to glycaemic control problems. However, our regional
subcohort analysis suggested that differences in pre-
treatment HbA1c (highest with insulin initiation) did not
explain observed drug differences. It is also possible that
a pre-existing predisposition to infections may have led
physicians to choose insulin versus other drugs as initial
pharmacotherapy. Furthermore, unmeasured confound-
ing due to combination of other factors such as those
related to unhealthy lifestyle and less social support
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might have inﬂuenced the risk of infections. Our sensi-
tivity analyses suggested that the observed weak associa-
tions between non-metformin GLDs and increased
antibiotic use may have been explained by differences in
smoking, although on the other hand, differences in
BMI and baseline HbA1c may have led to an underesti-
mation of the associations.
Our results for infections treated in the hospital
suggest either increased severity of infections associated
with speciﬁc GLDs or a lower threshold for hospitalising
a patient with a given infection, for example, due to
anticipated problems with glycaemic control or more
comorbidity/frailty among patients in these treatment
groups (surveillance bias). However, since we observed
consistent results for hospitalisations for severe infec-
tions, such as septicaemia, for which all patients are
likely to receive inpatient care, it is unlikely that our
results can be explained by increased surveillance alone.
As well, the initial GLD therapy choice may be altered,
which may lead to increasing exposure misclassiﬁcation
with longer follow-up periods. However, we observed
that less than one-quarter of our patients changed
therapy within the ﬁrst year of starting treatment with an
antidiabetic drug. Changes were most likely for patients
treated with insulin and sulfonylurea and thus unlikely
to explain their increased infection risk compared with
metformin users.
In conclusion, the present study provides evidence
that rates of infection are high in type 2 diabetes
patients during early treatment, and that pharmacother-
apy initiation with metformin may be associated with
reduced risk of hospital-treated infections, compared
with other GLDs.
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